Solace Pharmaceuticals Inc. Report issue

For profit Phase 2
Founded: Framingham MA United States (2006)
Status: Defunct (2010)

Organization Overview

First Clinical Trial
2009
NCT00813826
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Solace Brands, Inc. | Solace Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

cannabidiol (Epidiolex) (1 trial)

slc022 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2